Insilico Medicine Surges Nearly 38% Over Four Days Amid Multiple Drug R&D Partnerships and a $2.5B Deal with SK Biopharmaceuticals

Gelonghui, June 23 | Insilico Medicine (3696.HK) continued its counter-trend rally, rising as much as 13.29% to HK$45.34, hitting a new monthly high. The stock has risen for four consecutive days, accumulating a gain of approximately 38%. In the short term, the share price has successively broken through the 5-, 10-, 20-, and 30-day moving averages, with trading volume increasing compared to previous levels and relatively active trading.

In news developments, Insilico Medicine announced at midday yesterday that it had reached an AI-driven R&D collaboration with SK Biopharm worth up to $2.5 billion. Since the beginning of this year, Insilico Medicine has successively entered into pipeline out-licensing or drug development collaborations with Servier, Hengtai Bio (a subsidiary of Fosun Pharmaceutical), Qilu Pharmaceutical, CMS, Yuanyi Biotechnology, Eli Lilly, and SK Biopharm, bringing the total value of new agreements to nearly $6.5 billion. (Gelonghui)